Apellis Pharmaceuticals (APLS) News Today $27.00 -0.49 (-1.78%) (As of 10:31 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated by Analysts at Morgan StanleyMorgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a report on Thursday. They issued an "equal weight" rating and a $31.00 target price on the stock.November 21 at 7:42 AM | marketbeat.comVictory Capital Management Inc. Sells 49,960 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Victory Capital Management Inc. lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 10.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 411,906 sNovember 21 at 3:17 AM | marketbeat.comApellis Pharmaceuticals (APLS) Receives a Buy from JefferiesNovember 20 at 9:39 AM | markets.businessinsider.comApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up - Here's What HappenedApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up - Here's WhyNovember 19 at 11:00 AM | marketbeat.comApellis Pharmaceuticals: Strategic Advantage and Market Potential Boost with Syfovre’s Competitive EdgeNovember 19 at 9:26 AM | markets.businessinsider.comHold Rating on Apellis Pharmaceuticals Amid Regulatory Setbacks and Market UncertaintiesNovember 19 at 9:26 AM | markets.businessinsider.comGSA Capital Partners LLP Purchases Shares of 28,584 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)GSA Capital Partners LLP acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 28,584 shares of the company's stock, valuedNovember 17, 2024 | marketbeat.comApellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare ConferenceNovember 12, 2024 | markets.businessinsider.comFiera Capital Corp Sells 46,721 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Fiera Capital Corp lowered its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,354,469 shares of the company's stock after selling 46,7November 9, 2024 | marketbeat.comFY2024 Earnings Forecast for APLS Issued By HC WainwrightApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Apellis Pharmaceuticals in a report released on Wednesday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share oNovember 8, 2024 | marketbeat.comWhat is William Blair's Forecast for APLS FY2024 Earnings?Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at William Blair lowered their FY2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, November 5th. William Blair analyst L. Hanbury-Brown now anticipates tNovember 8, 2024 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $55.00 at Robert W. BairdRobert W. Baird dropped their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday.November 7, 2024 | marketbeat.comWedbush Cuts Earnings Estimates for Apellis PharmaceuticalsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush reduced their FY2024 earnings per share estimates for Apellis Pharmaceuticals in a report issued on Tuesday, November 5th. Wedbush analyst L. Chico now anticipates that the company will post earningsNovember 7, 2024 | marketbeat.comApellis Pharmaceuticals (APLS) Gets a Hold from ScotiabankNovember 6, 2024 | markets.businessinsider.comWells Fargo & Company Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $30.00Wells Fargo & Company cut their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Wednesday.November 6, 2024 | marketbeat.comPiper Sandler Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PricePiper Sandler cut their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a "neutral" rating for the company in a research report on Wednesday.November 6, 2024 | marketbeat.comOppenheimer Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceOppenheimer decreased their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an "outperform" rating on the stock in a research report on Wednesday.November 6, 2024 | marketbeat.com102,403 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by Old West Investment Management LLCOld West Investment Management LLC bought a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 102,403 sharesNovember 6, 2024 | marketbeat.comApellis drops as disappointing Syfovre sales drive Q3 missNovember 6, 2024 | msn.comApellis Pharmaceuticals: Long-Term Growth Potential for Syfovre Despite Short-Term Sales ChallengesNovember 6, 2024 | markets.businessinsider.comApellis Pharmaceuticals: Hold Rating Amid Revenue Miss and Financial ChallengesNovember 6, 2024 | markets.businessinsider.comApellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...November 6, 2024 | finance.yahoo.comNeedham & Company LLC Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $60.00Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday.November 6, 2024 | marketbeat.comHC Wainwright Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $57.00HC Wainwright reduced their target price on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a "buy" rating for the company in a research report on Wednesday.November 6, 2024 | marketbeat.comBank of America Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceBank of America cut their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a "buy" rating for the company in a report on Wednesday.November 6, 2024 | marketbeat.comWhy Apellis Pharmaceuticals Stock Was Tumbling on TuesdayNovember 5, 2024 | fool.comApellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comApellis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 5, 2024 | seekingalpha.comApellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month Low - Time to Sell?Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low - Time to Sell?November 5, 2024 | marketbeat.com47,500 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by AlphaCentric Advisors LLCAlphaCentric Advisors LLC bought a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 47,500 shares of the company's stock, valued at approximateNovember 5, 2024 | marketbeat.comApellis Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 5, 2024 | globenewswire.comApellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look ForNovember 4, 2024 | finance.yahoo.comRBC Capital Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)November 4, 2024 | markets.businessinsider.comApellis Pharmaceuticals (NASDAQ:APLS) Given Sector Perform Rating at Royal Bank of CanadaRoyal Bank of Canada reiterated a "sector perform" rating and issued a $25.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday.November 4, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Trims Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Allspring Global Investments Holdings LLC trimmed its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 91.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,52November 4, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Rating Increased to Strong-Buy at Evercore ISIEvercore ISI raised Apellis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday.November 2, 2024 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by AnalystsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating, twelve have issuedNovember 1, 2024 | marketbeat.comEvercore ISI Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)October 31, 2024 | markets.businessinsider.comQ1 Earnings Forecast for APLS Issued By William BlairApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at William Blair issued their Q1 2025 earnings estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, October 28th. William Blair analyst L. Hanbury-Brown anticipates that the company will postOctober 31, 2024 | marketbeat.comWhat is William Blair's Forecast for APLS Q4 Earnings?Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at William Blair issued their Q4 2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, October 28th. William Blair analyst L. Hanbury-Brown expects that the compaOctober 30, 2024 | marketbeat.comApellis Pharmaceuticals (APLS) to Release Earnings on TuesdayApellis Pharmaceuticals (NASDAQ:APLS) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638165)October 29, 2024 | marketbeat.com1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street AnalystOctober 29, 2024 | fool.comStifel Nicolaus Sticks to Their Buy Rating for Apellis Pharmaceuticals (APLS)October 28, 2024 | markets.businessinsider.comApellis Pharmaceuticals (APLS) Gets a Buy from TD CowenOctober 28, 2024 | markets.businessinsider.comShort Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expands By 38.2%Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 21,090,000 shares, a growth of 38.2% from the September 30th total of 15,260,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is presently 9.9 days.October 27, 2024 | marketbeat.comApellis, Sobi announced results from Phase 3 VALIANT studyOctober 27, 2024 | markets.businessinsider.comPivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNOctober 26, 2024 | globenewswire.comApellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Royal Bank of CanadaRoyal Bank of Canada began coverage on Apellis Pharmaceuticals in a research report on Friday. They set a "sector perform" rating and a $25.00 target price for the company.October 25, 2024 | marketbeat.comAssenagon Asset Management S.A. Purchases 1,409,707 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Assenagon Asset Management S.A. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 191.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,144,415 shares of the company's stock after acquiring an additionaOctober 25, 2024 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.550.46▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼88▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RIGL News OMER News MCRB News RDY News PCVX News CTLT News SRPT News QGEN News RVMD News ITCI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts